Smita N. Joshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Smita N. Joshi has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Sanjay Mehendale
3 shared publicationsB. Kishore Kumar
2 shared publicationsRamesh Paranjape
2 shared publicationsA Risbud
1 shared publicationArun Risbud
1 shared publication- Arun Risbud
National AIDS Research Institute, Pune, India
1 shared publication
Latest Publications
- 1 May 2009
- Vol. 129 (5) , 618-9
Challenges of introducing vaginal microbicides in India.
- 1 October 2008
- Published by BMJ in Sexually Transmitted Infections
- Vol. 84 (5) , 343-347
Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report
Background: Praneem, a candidate vaginal microbicide with reported anti-HIV and contraceptive properties was evaluated for its long-term safety through a double-blind, placebo-controlled, randomised phase II trial. Methodology: 142 women were screened and 100 HIV-uninfected, eligible women were enrolled, after obtaining written informed consents. Of these, 50 were randomly assigned to the study product arm and 50 to the placebo arm. Participants were requested to use the study product at least half an hour before each sexual act for 6 months. Results: Participants in both treatment groups contributed 601 person-months of follow-up and 95% of the participants completed the last follow-up. Although transient genital discomfort was the main reported adverse experience, none of the study participants discontinued product use. Most of the adverse events were mild and there were no serious adverse events related to study product use and no HIV seroconversions. Discussion: Praneem polyherbal tablet was safe for vaginal use up to 6 months with each act of sex among low-risk women. In light of the failure of Nonoxynol-9, cellulose sulphate and Carraguard in preventing HIV infections among women, additional preclinical evaluations should be undertaken urgently before moving into effectiveness studies.
- 1 October 2008
- Published by BMJ in Sexually Transmitted Infections
- Vol. 84 (5) , 343-347
Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report
Background: Praneem, a candidate vaginal microbicide with reported anti-HIV and contraceptive properties was evaluated for its long-term safety through a double-blind, placebo-controlled, randomised phase II trial. Methodology: 142 women were screened and 100 HIV-uninfected, eligible women were enrolled, after obtaining written informed consents. Of these, 50 were randomly assigned to the study product arm and 50 to the placebo arm. Participants were requested to use the study product at least half an hour before each sexual act for 6 months. Results: Participants in both treatment groups contributed 601 person-months of follow-up and 95% of the participants completed the last follow-up. Although transient genital discomfort was the main reported adverse experience, none of the study participants discontinued product use. Most of the adverse events were mild and there were no serious adverse events related to study product use and no HIV seroconversions. Discussion: Praneem polyherbal tablet was safe for vaginal use up to 6 months with each act of sex among low-risk women. In light of the failure of Nonoxynol-9, cellulose sulphate and Carraguard in preventing HIV infections among women, additional preclinical evaluations should be undertaken urgently before moving into effectiveness studies.
- Open Access
- 1 January 2006
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 3 (1) , 4
Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India
- 1 January 2006
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 3 (1) , 4
Open AccessPhase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India
- 1 November 2005
- Published by Elsevier in Contraception
- Vol. 72 (5) , 366-371
Comparative acceptability study of the Reality® female condom and the version 4 of modified Reddy female condom in India
- 1 November 2005
- Published by Elsevier in Contraception
- Vol. 72 (5) , 366-371
Comparative acceptability study of the Reality® female condom and the version 4 of modified Reddy female condom in India
- 1 October 2005
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 99 (10) , 769-774
Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India
Praneem polyherbal formulations containing purified extracts of Azadirachta indica (neem tree) have shown activity against HIV and sexually transmitted disease pathogens in studies in vitro. The product also has contraceptive properties. This has prompted its development as a possible microbicide. We evaluated the safety of Praneem polyherbal tablet use among HIV-uninfected women. Twenty eligible women were enrolled in a Phase I open-label study requiring 14 days of consecutive intravaginal use of Praneem polyherbal tablets. Nine (45%) participants experienced 17 episodes of genital irritation. Transient genital itching was reported by eight (40%) participants, burning micturation by two (10%) and lower abdominal pain, genital burning and intermenstrual spotting by one (5%) each. On colposcopy, petechial haemorrhage was observed in two participants, one on day 7 and the other on day 14, and both were resolved without any treatment. There were no serious adverse events. Praneem polyherbal tablets were found to be safe for once daily intravaginal use for 14 consecutive days in sexually active HIV-uninfected women and a Phase II study may be taken up as a priority.
- 1 October 2005
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 99 (10) , 769-774
Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India
Praneem polyherbal formulations containing purified extracts of Azadirachta indica (neem tree) have shown activity against HIV and sexually transmitted disease pathogens in studies in vitro. The product also has contraceptive properties. This has prompted its development as a possible microbicide. We evaluated the safety of Praneem polyherbal tablet use among HIV-uninfected women. Twenty eligible women were enrolled in a Phase I open-label study requiring 14 days of consecutive intravaginal use of Praneem polyherbal tablets. Nine (45%) participants experienced 17 episodes of genital irritation. Transient genital itching was reported by eight (40%) participants, burning micturation by two (10%) and lower abdominal pain, genital burning and intermenstrual spotting by one (5%) each. On colposcopy, petechial haemorrhage was observed in two participants, one on day 7 and the other on day 14, and both were resolved without any treatment. There were no serious adverse events. Praneem polyherbal tablets were found to be safe for once daily intravaginal use for 14 consecutive days in sexually active HIV-uninfected women and a Phase II study may be taken up as a priority.
- 23 June 2005
- Published by Wiley in Journal of Medical Virology
- Vol. 76 (4) , 470-475
Cervical squamous intra-epithelial changes and human papillomavirus infection in women infected with human immunodeficiency virus in Pune, India
- 23 June 2005
- Published by Wiley in Journal of Medical Virology
- Vol. 76 (4) , 470-475
Cervical squamous intra-epithelial changes and human papillomavirus infection in women infected with human immunodeficiency virus in Pune, India
- 1 April 2005
- Vol. 121 (4) , 502-9
Preparing for efficacy trials of vaginal microbicides in Indian women.
Vaginal microbicides are topical compounds that are expected to protect women against vaginal transmission of HIV and other sexually transmitted pathogens. A large number of compounds are being evaluated as possible microbicides. Considering the spread of the HIV epidemic among women in India, clinical trials on microbicides starting from the Phase I safety and acceptability studies to Phase III efficacy trials are important. Conducting efficacy trials is a major endeavour and this review discusses challenges and issues and the preparatory steps to make such efficacy trials possible in India.
- 1 April 2005
- Vol. 121 (4) , 502-9
Preparing for efficacy trials of vaginal microbicides in Indian women.
Vaginal microbicides are topical compounds that are expected to protect women against vaginal transmission of HIV and other sexually transmitted pathogens. A large number of compounds are being evaluated as possible microbicides. Considering the spread of the HIV epidemic among women in India, clinical trials on microbicides starting from the Phase I safety and acceptability studies to Phase III efficacy trials are important. Conducting efficacy trials is a major endeavour and this review discusses challenges and issues and the preparatory steps to make such efficacy trials possible in India.